Icon Plc $ICLR Holdings Boosted by Hunter Perkins Capital Management LLC

by · The Cerbat Gem

Hunter Perkins Capital Management LLC grew its stake in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 18.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,470 shares of the medical research company’s stock after purchasing an additional 4,071 shares during the quarter. Hunter Perkins Capital Management LLC’s holdings in Icon were worth $4,632,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ICLR. Artisan Partners Limited Partnership boosted its position in Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after purchasing an additional 2,893,946 shares during the period. Harris Associates L P acquired a new stake in Icon in the second quarter worth $238,256,000. Norges Bank bought a new stake in Icon in the second quarter valued at $158,639,000. 1832 Asset Management L.P. boosted its holdings in shares of Icon by 587.9% during the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock valued at $167,461,000 after acquiring an additional 983,950 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in shares of Icon during the second quarter worth about $94,814,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Price Performance

NASDAQ ICLR opened at $183.64 on Thursday. Icon Plc has a 12 month low of $125.10 and a 12 month high of $228.29. The firm has a market capitalization of $14.83 billion, a PE ratio of 24.85, a P/E/G ratio of 3.39 and a beta of 1.25. The company’s 50 day simple moving average is $175.50 and its 200 day simple moving average is $169.31. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ICLR shares. Cowen reiterated a “hold” rating on shares of Icon in a research report on Friday, October 24th. Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Leerink Partners set a $220.00 price objective on Icon in a report on Thursday, October 23rd. TD Cowen cut their target price on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Finally, Barclays boosted their price target on Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.31.

Get Our Latest Stock Analysis on ICLR

About Icon

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Further Reading

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR – Free Report).